Business Context and Reporting Period
Company: SciSparc Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Date: March 27, 2024
Principal Executive Offices: Tel Aviv, Israel
Context: This filing reports a corporate development regarding a collaboration with Clearmind, specifically the submission of a new international patent application focused on preventing and treating depression.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K is a current report of a specific event and does not contain financial statements or performance metrics.
Material Changes
Collaboration Update: SciSparc Ltd. and Clearmind have advanced their collaboration with the filing of a new international patent application.
Focus Area: The patent application targets the prevention and treatment of depression.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release detailing the patent application but does not include specific financial guidance, future outlook projections, or a discussion of risks and contingencies within the text of this report.
Unusual Items: None reported in this filing.
Investor Verification Checklist
- Verify the scope and status of the new international patent application for depression treatment.
- Review the full text of the press release (Exhibit 99.1) for details on the SciSparc-Clearmind collaboration terms.
- Check subsequent filings for any financial impact or milestone payments related to this patent development.
- Confirm the regulatory status of the depression treatment technology in relevant jurisdictions.